Trial Profile

Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary) ; Trabectedin (Primary)
Indications Leiomyosarcoma; Soft tissue sarcoma
Focus Therapeutic Use
Acronyms TOMAS2

Most Recent Events

04 Dec 2024 Status changed from active, no longer recruiting to completed.
24 Oct 2023 Primary endpoint has not been met. (Progression free Survival (PFS)) , according to presented at the 48th European Society for Medical Oncology Congress
24 Oct 2023 Results assessing feasibility and preliminary activity data of T+O at a median follow-up of 10.2 months presented at the 48th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com